Golimumab improves work productivity in patients suffering from moderate to severe ulcerative colitis: results of a prospective study over 24 months

Golimumab improves work productivity in patients suffering from moderate to severe ulcerative colitis: results of a prospective study over 24 months

Abstract Background Ulcerative colitis (UC) is a chronic inflammatory bowel disease with recurrent episodes of debilitating symptoms negatively affecting work productivity and health-related quality of life (HRQoL). The use of biologics in UC treatment improves work and HRQoL but prospective long-te...

Full description

Bibliographic Details
Main Authors: Niels Teich, Harald Grümmer, Eric Jörgensen, Thomas Liceni, Frank Holtkamp-Endemann, Tim Fischer, Susanne Hohenberger
Format: Article
Language:English
Published: BMC 2021-04-01
Series:BMC Gastroenterology
Subjects:
Golimumab
Ulcerative colitis
Work productivity and activity impairment (WPAI)
Quality of life
Hospitalization
Health care resource utilization (HCRU)
Online Access:https://doi.org/10.1186/s12876-021-01747-z

Internet

https://doi.org/10.1186/s12876-021-01747-z

Similar Items